drugset
drugset / Trial / NCT03831607

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

NCT03831607 ↗

Phase 2 Completed 67 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.

Timeline

Start
2018-12-27
Primary completion
2019-11-26
Completion
2019-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule — —

Indications

hyperphosphatemia